Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

Dimitrios Daoussis (1) , Andrew P. Andonopoulos (1)

1 Division of Rheumatology, Department of Internal Medicine, Patras University Hospital

Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.

Mots clés: Systemic sclerosis; Scleroderma; Rituximab; Interstitial lung disease; B cells; Fibrosis; Skin thickening; Rheumatic diseases

Dimitrios Daoussis, Andrew P. Andonopoulos. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo. Rheumatology International, 2010, 31 (6), pp.841-842. ⟨10.1007/s00296-010-1485-3⟩. ⟨hal-00615347⟩